Drug Profile

Gallium-68 NY 108 - Norroy Bioscience

Alternative Names: 68Ga-NYM-032; 68Ga-NYM032 PET/CT; Gallium-68 NY-108; Gallium-68 NY108 PET/CT; Gallium-68 NYM 032

Latest Information Update: 24 Aug 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Norroy Bioscience
Class Gallium radioisotopes; Imaging agents; Radioisotopes; Radiopharmaceutical diagnostics; Small molecules
Mechanism of Action Positron-emission tomography enhancers

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

06 Aug 2026 Phase-III clinical trials in Prostate cancer (Diagnosis, First-line therapy) in China (IV) (NCT07615101)
16 Jun 2026 Norroy Bioscience plans a phase III trial for Prostate Cancer (Diagnosis) in June 2026 (IV injection) (NCT07649122)
01 Jun 2026 Norroy Bioscience plans a phase-III trial for Prostate cancer (Diagnosis) (IV, injection) (NCT07615101)

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com